Innovative Immunotherapeutic Strategies: Maximizing Treatment of Head and Neck Cancer

FACULTY

Barbara Burtness, MD
Professor of Medicine
Co-Leader, Developmental Therapeutics Program
Interim Associate Director, Diversity Equity and Inclusion
Director, Yale Head and Neck SPORE
New Haven, CT

Saral Mehra, MD, MBA, FACS
Associate Professor of Surgery (Otolaryngology)
Section Chief, Head and Neck Surgery
Director, Fellowship in Head and Neck Surgery Yale University and Smilow Cancer Hospital at YNHHS
New Haven, CT

Lynsey Teulings, APRN
Yale Cancer Center
New Haven, CT

PROGRAM OVERVIEW

This educational activity will explore the appropriate place in the therapy paradigm for immunotherapy in patients with head and neck cancer, as well as managing adverse effects of immunotherapies.

TARGET AUDIENCE

This activity is designed to meet the educational needs of medical oncologists, surgical oncologists, and other healthcare professionals who manage patients with head and neck squamous cell carcinoma.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Summarize clinical trial data on relevant biomarkers to predict response to immunotherapy in head and neck squamous cell carcinoma (SCCHN)
• Evaluate treatment guideline considerations and clinical trial data to appropriately sequence and combine therapies in the management of SCCHN
• Evaluate strategies to identify and manage immune-related adverse events associated with immune checkpoint inhibitors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with squamous cell head and neck carcinoma.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

• Dr. Burtness has received consulting fees from Aduro, Alligator Bioscience, Rakuten Medical, Maverick Therapeutics, Debiopharm, Celegene, CUE Biopharma, GSK, Nanobiotix and Merck & Co., Inc. Astra Zeneca, ALX Oncology, Vaccinex, Merck KgA, Merck, Roche, Exelexis, Cue BioPharma, Nektar, Kura
• Dr. Mehra has no disclosures.
• Ms. Teulings no disclosures.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
• Debra Gordon, MS, Medical Director for Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
• Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
• Daniel Dasilva, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
• Rashado Coote, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for enduring this activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete pre-and-post surveys and evaluation

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASED DATE: November 04, 2022
EXPIRATION DATE: November 04, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.